Jiangsu Vcare's Next-Generation TRK Inhibitor VC004 Completes First Patient Enrollment in China's Pivotal Phase II Trial
Published Time:
2024-01-04 17:56
Source:
Recently, Jiangsu Vcare Pharmaceutical Technology Co., Ltd. (Jiangsu Vcare) completed the first patient enrollment in the pivotal Phase II clinical trial (Registration Number: CTR20201703) in China for its self-developed next-generation TRK inhibitor, VC004. This clinical trial aims to further evaluate the efficacy and safety of VC004 in treating patients with NTRK gene fusion mutations.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "VC004 is a next-generation TRK inhibitor prioritized by our company. With its unique mechanism of action and favorable safety profile, as well as significant clinical efficacy demonstrated in early clinical studies, we believe it has the potential to be the leading drug among similar next-generation TRK inhibitors. The completion of the first patient enrollment in this pivotal Phase II trial marks another significant milestone in VC004's clinical development. We will accelerate its subsequent clinical development process, expediting the exploration of its safety and efficacy in patients with NTRK fusion-positive solid tumors, striving to bring this resistance-overcoming TRK targeted therapy to cancer patients as soon as possible."
About VC004
VC004 is a Class I targeted agent independently developed by Jiangsu Vcare. As a next-generation TRK inhibitor, it's expected to provide a treatment option for patients with NTRK fusion mutations, addressing the unmet clinical need for anti-resistance therapy globally. Phase I clinical data show an ORR of 80-90% in patients with NTRK fusion-positive solid tumors, with the longest DOR reaching 24 months. Efficacy data collection is ongoing. Preliminary efficacy was also observed in patients with brain metastases and those previously treated with TRK inhibitors, with over 60% of brain metastasis patients showing varying degrees of tumor shrinkage, including one case where the lesion nearly disappeared. Currently, no next-generation resistance-overcoming inhibitors are marketed globally. VC004 has the potential to become a leading next-generation TRK inhibitor worldwide.
About NTRK Fusion-Positive Solid Tumors
NTRK gene fusions have been identified as oncogenic drivers in both adult and pediatric patients with a wide range of solid tumors. The NTRK genes (NTRK1, NTRK2, and NTRK3) encode the TRKA, TRKB, and TRKC receptors of the TRK family. These fusions act as drivers in multiple cancers and are found across numerous solid tumor types. Currently, NTRK fusion inhibitors show remarkable efficacy in the clinical practice, holding immense potential in the field of oncology. In China, NTRK gene fusion mutations are found in prevalent cancer types such as lung cancer, colorectal cancer, breast cancer, and thyroid cancer, especially high prevalence in certain rare cancers, including secretory breast carcinoma and salivary gland secretory carcinoma.
Related News
30
2024
/
12
On December 30, 2024, the first administration of VC005 tablets was completed in the Phase III clinical trial of oral treatment of moderate-to-severe atopic dermatitis (AD). VC005 is a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare). Positive top-line data were obtained from the unblinded Phase II clinical study of VC005 for AD, with primary endpoints showing superiority over the best drugs in the same class. Meanwhile, the overall safety and tolerability of the drug are good. In particular, the decreases in neutrophil and platelet counts caused by high dosage VC005 were smaller, compared with the positive control group of tofacitinib, and no significant reduction in lymphocyte count was observed.
View Details
18
2024
/
11
Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"
At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.
View Details
01
2024
/
11
Recently, the Nanjing Municipal Science and Technology Bureau announced the acceptance results of 2024 provincial-level engineering research centers and academician workstations. The"Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center", established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), successfully passed project acceptance.
View Details
28
2024
/
10
Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"
Recently, the Jiangsu Provincial Department of Science and Technology announced the "2024 Proposed Enterprises for Provincial Sci-Tech Enterprise Listing Cultivation Program," withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) successfully included.
View Details
23
2024
/
10
Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
View Details
22
2024
/
10
Jiangsu Vcare's Oral Treatment VC005 for Atopic Dermatitis enters Phase III Clinical Study
VC005 tablets, developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare), is a new-generation highly selective JAK1 inhibitor. The oral treatment of moderate-to-severe atopic dermatitis has initiated a Phase III clinical trial. It is a multicenter, randomized, double-blind, placebo parallel-controlled Phase III clinical study, aiming to evaluate the efficacy and safety of VC005 tablets for adult patients with moderate-to-severe atopic dermatitis. The trial is led by the Institute of Dermatology, Chinese Academy of Medical Sciences.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn